Efficacy News and Research

RSS

Opinions: IDUs and HIV; AIDS 2010; International Violence Against Women Act

In a Los Angeles Times opinion piece, Evan Wood, associate professor of medicine at the University of British Columbia, writes about the Vienna Declaration, a document he helped to draft, that calls for international leaders to revise drug policies to incorporate greater scientific evidence and promote HIV prevention, treatment and care for drug users.

31 Jul 2010

Functional MRI can be used to assess tumor viability

Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancer. As current treatments offer minimal benefit, entirely new approaches are needed. Given the success of local therapies, as opposed to intravenous systemic therapies, for liver diseases (such as hepatocellular carcinoma), it is thought that similar local therapies may benefit patients with pancreatic cancer. To develop such therapies, it would be useful to devise targets that are easy to obtain and can indicate the efficacy of these new therapies in models of pancreatic cancer.

31 Jul 2010

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, high market opportunity in the European embolization coil market has led to several major acquisitions in 2010. The European market alone was valued at approximately $100 million in 2009, making successful niche competitors in this market attractive acquisition targets.

30 Jul 2010

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

Cerus second-quarter product revenue for INTERCEPT Blood System increases 47% to $5.7 million

Cerus Corporation today announced financial results for the second quarter ended June 30, 2010.

30 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

30 Jul 2010

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.

30 Jul 2010

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.

30 Jul 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.

30 Jul 2010

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).

30 Jul 2010

Transforaminal injection of steroids is a viable alternative for lumbar radicular pain surgery

A recent study from Australian researchers determined that transforaminal injection of steroids was a viable alternative to surgery for lumbar radicular pain due to disc herniation. Full details of the study appear in the August issue of Pain Medicine, a journal published by Wiley-Blackwell on behalf of the American Academy of Pain Medicine, the Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists, and the International Spine Intervention Society.

30 Jul 2010

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has been granted approval by the Japanese Pharmaceutical and Medical Devices Agency to import and distribute the AED Plus and AED Pro in Japan.

29 Jul 2010

ZOLL Medical revenues for third-quarter fiscal 2010 up 17% to $111.3 million

ZOLL Medical Corporation, a manufacturer of resuscitation devices and software solutions, today announced that revenues for the third quarter of fiscal 2010 increased 17% to $111.3 million, compared to revenues in the third quarter of last year of $95.1 million. The third quarter 2010 results included approximately $5.0 million of revenue from the Temperature Management business, compared to $1.9 million of revenue in the third quarter of last year.

29 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours.

29 Jul 2010

ACT responds to FDA queries on Phase I/II study using ES cell derived retinal cells to treat SMD

Advanced Cell Technology, Inc. announced today that it has submitted documentation and a complete response to substantively address the issues raised by the US Food and Drug Administration (FDA) in connection with the Company's plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).

29 Jul 2010

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

NDS Surgical Imaging introduces ConnectOR G2 visualization and informatics platform

NDS Surgical Imaging (NDSsi) today launched its next-generation visualization and informatics platform—the ConnectOR G2—with production units now shipping to customers. Based on the NDSsi technology vision of Medical Visualization Informatics (MVI), ConnectOR G2 medical-grade products are leading the industry in procedural efficacy by offering the unique ability to connect the realms of PACS imaging, surgical video and medical informatics.

29 Jul 2010

Efficacy News and Research

Opinions: IDUs and HIV; AIDS 2010; International Violence Against Women Act

Functional MRI can be used to assess tumor viability

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Cerus second-quarter product revenue for INTERCEPT Blood System increases 47% to $5.7 million

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

Transforaminal injection of steroids is a viable alternative for lumbar radicular pain surgery

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

ZOLL Medical revenues for third-quarter fiscal 2010 up 17% to $111.3 million

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

AVEO second-quarter total revenues increase to $15.6 million

Rotigotine provides clinically relevant improvements in RLS symptoms: Study

ACT responds to FDA queries on Phase I/II study using ES cell derived retinal cells to treat SMD

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

NDS Surgical Imaging introduces ConnectOR G2 visualization and informatics platform

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News